9999999997-23-004515.txt : 20231010 9999999997-23-004515.hdr.sgml : 20231010 20231010170002 ACCESSION NUMBER: 9999999997-23-004515 CONFORMED SUBMISSION TYPE: SEC STAFF ACTION CATEGORY: ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20231010 ACTION DATE: 20231010 RECEIVED DATE: 20231010 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: SEC STAFF ACTION BUSINESS ADDRESS: STREET 1: 10102 USA TODAY WAY CITY: MIRAMAR STATE: FL ZIP: 33025 BUSINESS PHONE: 416-364-2551 MAIL ADDRESS: STREET 1: 10102 USA TODAY WAY CITY: MIRAMAR STATE: FL ZIP: 33025 ORDER 1 filename1.pdf begin 644 filename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